Arbutus Biopharma logo
Arbutus Biopharma
ABUS | NASDAQ
Chart Builder DCF Calculator
$4.04
-$0.05 (-1.22%)
At close: Nov 16, 2026, 4:00 PM ET
$4.17
+$0.13 (+3.22%)
After-hours: Nov 16, 2026, 7:33 PM ET

Arbutus Biopharma Company Profile

Company profile explained

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Key Executives

Name Position
Lindsay Androski President, Chief Executive Officer & Chairman
Tuan Nguyen Chief Financial Officer
Andrew J. Sung General Counsel
R. Hector Mackay-Dunn Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 22, 2026 8-K Current Report
Oct 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 05, 2026 SC 13D/A [Amend] Filing
Oct 05, 2026 4 Filing
Oct 01, 2026 SC TO-I/A [Amend] Filing
View All SEC Filings ➞
Arbutus Biopharma
Arbutus Biopharma logo
Country United States
IPO Date Jul 26, 2007
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Lindsay Androski

Contact Details

701 Veterans Circle Warminster, Pennsylvania 18974 United States

Stock Details

Ticker Symbol ABUS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001447028
CUSIP Number 03879J100
ISIN Number CA03879J1003
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.